Researchers trace two new biomarkers for atrial fibrillation that increases risk of stroke and heart failure
Researchers at the University of Birmingham have found two biomarkers that could be used to identify atrial fibrillation.
Atrial fibrillation is the most common heart rhythm disturbance, affecting around 1.6 million people in the UK. Those with atrial fibrillation may be aware of noticeable heart palpitations, when their heart feels like it is pounding, fluttering or beating irregularly. Sometimes atrial fibrillation does not cause any symptoms and a person who has it is completely unaware that their heart rate is irregular.
Scientists have concluded that patients are more at risk of atrial fibrillation if they have three ‘clinical risks’ – they are older aged, male and have a high Body Mass Index. These patients, say the scientists, could be screened for atrial fibrillation by testing their blood to see if they have elevated levels of two biomarkers – a hormone secreted by the heart called brain natriuretic peptide (BNP) and a protein responsible for phosphate regulation called fibroblast growth factor-23 (FGF-23).
“Atrial fibrillation increases the risk of stroke, a serious condition that causes over 36,000 deaths in the UK each year, but is often detected too late.”
The research was carried out by scientists from the Institute of Cardiovascular Sciences and the Institute of Cancer and Genomic Sciences at the University of Birmingham’s College of Medical and Dental Sciences. It has been published in European Heart Journal.
First author Dr Winnie Chua said: “People with atrial fibrillation are much more likely to develop blood clots and suffer from strokes. To avoid strokes it is important for them to take anticoagulant drugs to prevent blood clotting. However, atrial fibrillation is often only diagnosed after a patient has suffered a stroke. Therefore it is important that patients at risk are screened so that they can begin taking anticoagulants to prevent potentially life-threatening complications.”
Until now, most studies identifying biomarkers in patients with atrial fibrillation have been hypothesis-driven. They involved the analysis of a single or small selection of blood biomarkers. In this study, the scientists analysed 40 common cardiovascular biomarkers in a cohort of 638 hospital patients who were recruited between September 2014 and August 2016.
To obtain the results, the scientists combined traditional statistical analysis with completely new and innovative machine learning techniques.
Senior author Dr Larissa Fabritz said: “The research outcomes were surprising. While BNP is already a known and widely used in clinical practice biomarker, the results around the effectiveness of the FGF-23 biomarker was an unexpected and new finding. FGF-23 is only currently used in a research based environment, but we have shown how its use could be invaluable in a clinical setting.”
Funded by the University of Birmingham, the research was supported by CATCH ME, an EU-funded consortium led by the University of Birmingham, the British Heart Foundation and Leducq Foundation. The research was carried out in collaboration with Sandwell and West Birmingham Hospitals NHS Trust, University Hospitals Birmingham NHS Foundation Trust, the European Society of Cardiology, The German Atrial Fibrillation NETwork (AFNET), and Health Data Research UK.
Professor Metin Avkiran, Associate Medical Director at the British Heart Foundation (BHF), added: “Atrial fibrillation increases the risk of stroke, a serious condition that causes over 36,000 deaths in the UK each year, but is often detected too late. This research has used sophisticated statistical and machine learning methods to analyse patient data and provides encouraging evidence that a combination of easy-to-measure indices may be used to predict atrial fibrillation.”